27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Ikena Oncology Inc (NASDAQ:IKNA) nominated a next-generation mitogen-activated protein kinase (MEK)-RAF complex inhibitor, IK-595, as its first development candidate in the RAS pathway.
- The company plans to submit an investigational new drug application (IND) for IK-595 to the FDA in the second half of 2023.
- The company's paralog-selective TEAD inhibitor IK-930 is advancing as planned in dose escalation. Monotherapy clinical data is expected in 2H 2023.
- Preclinical data on differentiation and advantages of paralog selectivity are planned for presentation in the first half of 2023.
- Following a portfolio review, the company is discontinuing the internal clinical development of the EP4 antagonist IK-007 and exploring strategic alternatives for this program.
- Portfolio reprioritization and streamlining of discovery and clinical activities contribute to extending the cash runway into 2025.
- Price Action: IKNA shares are up 5.59% at $2.49 on the last check Monday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!